Intravenous administration of bolus 5-fluorouracil (5-FU) and leucovorin (LV) has been a standard treatment regime for stage III CRC
Fluorouracil (5-FU) remains the most widely used agent for colorectal cancer
Capecitabine - LiverTox - NCBI Bookshelf Capecitabine is a pyrimidine analogue used as an antineoplastic agent to treat metastatic and advanced forms of breast and colon cancer, often in combination with other agents
Capecitabine was noninferior to 5fluorouracil and leucovorin (5-FU/LV) for disease-free survival; consider results of combination chemotherapy trials, which have shown improvement in disease-free and overall survival, when prescribing single-agent capecitabine in the adjuvant setting The results are consistent with our study
078 Patients were randomly assigned either to the experimental group receiving fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) or to the control group receiving epirubicin and cisplatin plus either fluorouracil or capecitabine (ECF/ECX)
com
Patients and methods: This analysis compared all published CAP/OX versus infusional FU/OX regimens
2011 Feb 1;128(3):682-90
Standard therapy for advanced or metastatic colorectal cancer consists of 5-fluorouracil plus leucovorin (5-FU/LV) administered intravenously (i
Die Ergebnisse zeigen, dass die Kombination von Fluorouracil, Leucovorin, Oxaliplatin und Docetaxel zu einer längeren Überlebenszeit und einer höheren Ansprechrate führt als Fluorouracil Purpose: To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer
Despite these changes, intravenous fluorouracil chemotherapy remains an important component of treatment for metastatic colorectal cancer, generally combined with leucovorin plus oxaliplatin (FOLFOX) or Colorectal cancer is an umbrella term that refers to cancer of both the colon and the rectum
neurological issues, such Purpose Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC)
Use Caution/Monitor
It is FDA-approved in combination with infusional 5-fluorouracil and leucovorin
After a standard dosage of 1250 mg/m 2, the peak plasma concentration is achieved in 1
Capecitabine (Xeloda) prevents cancer cells from spreading by interfering with the genetic material
4 Gy, although there were two types of additional chemotherapies
Day 1: Leucovorin 400mg/m 2 IV over 2 hours to match the infusion time of oxaliplatin, followed by: Results
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Patients with locally advanced or metastatic gastric or EGJ cancer were Overall direct costs for the 24-week treatment period were less with capecitabine than 5-FU/LV (NT$129,327 vs
However, several studies have shown that oral therapy with UFT/L or capecitabine is as effective as intravenous (i
Patients and methods: Patients with stage III colon carcinoma were randomly assigned to receive either XELOX (intravenous oxaliplatin plus oral capecitabine; 3-week cycle for eight cycles) or standard intravenous bolus FU/LV administered as the Mayo Clinic (Mayo; Rochester, MN) or Roswell Park (RP; Buffalo, NY) regimen for a similar length of The evidence is limited to suggest that XELOX may share similar efficacy as FOLFOXs and reduce toxicities of chemotherapy in advanced gastric cancer therapy
49, 50 The combination is usually administered together with oral leucovorin and is approved by regulatory There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m2, day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m2, day 1, every 14 days)
Primarily, efficacy and Liều capecitabine tối đa phải giảm còn 2000 mg/ngày khi dùng đồng thời interferon alpha-2a (3 MUI/m2/ngày) Nếu kết hợp với xạ trị ung thư trực tràng, liều tối đa capecitabine là 2000 mg/ngày
Capecitabine (Xeloda®: F Hoffmann-La Roche, Basel, Switzerland) is an oral fluoropyrimidine carbamate rationally designed to generate 5-FU preferentially in tumour
Neoplasm Metastasis
British Journal of Cancer - Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised
Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients
The phase III TRIBE study demonstrated that fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) combination plus bevacizumab has better
A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)
Patients and methods: This analysis compared all
Second, the response rate and survival time exhibited an improvement of almost double when 5-FU administration was combined with the biomodulatory agent leucovorin (LV)
PATIENTS AND METHODS: We prospectively randomized 605 patients to treatment with oral
Diese Studie vergleicht die Wirksamkeit und Sicherheit von zwei verschiedenen Chemotherapie-Regimen bei Patienten mit lokal fortgeschrittenem, operablem Magen- oder gastroösophagealen Übergangskarzinom
Patients were randomly assigned either to the experimental group receiving fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) or to the control group receiving epirubicin and cisplatin plus either fluorouracil or capecitabine (ECF/ECX)
Patients received capecitabine 1,250 mg/m 2 orally twice daily for the first 14 days of a 21-day cycle ( N = 995) or leucovorin 20 mg/m 2 intravenously followed by fluorouracil 425 mg/m 2 as an intravenous bolus on days 1 to 5 of each 28-day cycle (N = 974)
Standard therapy for advanced or metastatic colorectal cancer consists of 5-fluorouracil plus leucovorin (5-FU/LV) administered intravenously (i
Capecitabine (Xeloda ®, Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil (5-FU), and it is converted to 5-FU in the cancer cell by enzymatic degradation
Therefore, we aimed to compare the efficacy and safety of the mXELIRI regimen with that of standard FOLFIRI (leucovorin, fluorouracil, and irinotecan), with or Adjuvant chemotherapy of leucovorin-modulated 5-fluorouracil (5-FU/LV), capecitabine, and adding oxaliplatin to 5-FU/LV or capecitabine (FLOX/OX) have been standard regimens for high-risk stage II or III colon cancer (CC)
7 out of 10 from a total of 3 ratings on Drugs